Xiaohua Gong

Publication Activity (10 Years)

Years Active: 2022-2024
Publications (10 Years): 5

Top Topics

Heart Rate Variability

Hodgkin Lymphoma

Top Venues

Pharmacology research & perspectives

American journal of clinical dermatology

This page only lists publications with an associated author ORCID identifier.

Publications

Jia Li, Xiaohua Gong, Xing Liu, Xiang Liu, Ke Szeto, Xuejun Chen
Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study. Pharmacology research & perspectives 12 (2) (2024)
Jia Li, Xiaohua Gong, Xing Liu, Xiang Liu, Ke Szeto, Xuejun Chen
Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study. Pharmacology research & perspectives 12 (2) (2024)
Jia Li, Xiaohua Gong, Xing Liu, Xiang Liu, Ke Szeto, Xuejun Chen
Evaluation of the cardiac safety of parsaclisib, a selective PI3Kδ inhibitor, in patients with previously treated B-cell malignancies: Results from the CITADEL-101 study. Pharmacology research & perspectives 12 (2) (2024)
Xiaohua Gong, Tao Ji, Xiang Liu, Xuejun Chen, Swamy Yeleswaram
Evaluation of the clinical cardiac safety of pemigatinib, a fibroblast growth factor receptor inhibitor, in participants with advanced malignancies. Pharmacology research & perspectives 10 (1) (2022)
Robert Bissonnette, Robert S Call, Tooraj Raoof, Zhaoyin Zhu, Swamy Yeleswaram, Xiaohua Gong, Mark Lee
A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis. American journal of clinical dermatology 23 (3) (2022)